John Garner

PLGA used for development of nanoparticle based chlamydia vaccine delivery

Blog Post created by John Garner on Feb 8, 2016

PolySciTech ( provides a wide array of biodegradable polyesters including PLGA. Recently, researchers are Alabama State University, used this kind of polymer for the delivery of rMOMP-187 peptide to elicit a genital mucosal Th1 response. The researchers established that this delivery system induced macrophages to display an immune response thus showing potential for prevention of chlamydia. This research has the potential to provide for an effective vaccine against chlamydia. This is particularly valuable as the incidence of chlamydia infections as of 2008 was 105.7 million cases and rising (WHO, Global incidence and prevalents of selected curable sexually transmitted infections – 2008). Read more about this research here: Taha, M., S. R. Singh, C. Butler, E. Nyairo, and V. A. Dennis. "Characterization of rMOMP-187 Peptide Encapsulated in PLGA 50: 50 Nanoparticles." une 13 (2016): 15.


  “Abstract: The design of an immunization regimen capable of inducing sustained genital mucosal Th1 response is the current goal for a vaccine for humans to control the severe complications of genital infection by C. trachomatis. In this research, gene fragments of the MOMP gene containing T and B-cell epitopes (corresponding to amino acids 187 – 344) were expressed in E. coli cells, purified and encapsulated in PLGA 50:50 nanoparticles. The efficacy of rMOMP-187–PLGA nanoparticles was evaluated in vitro in J774 macrophages. Our data shows that rMOMP-187 encapsulated in PLGA 50:50 nanoparticles has the potential to induce immune responses in vivo and hence further studies are underway to confirm its usefulness as a promising vaccine candidate against Chlamydia. The anticipated results will provide the foundation for full- scale research on the antibody immunity characteristics of recombinant MOMP-PLGA as a potential candidate against Chlamydia. Keywords: Chlamydia, rMOMP, PLGA”